Odyssey Health, Inc.

For the period ended Apr 30, 2025. Filed Jun 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Apr 30, 2025 · Filed Jun 13, 2025

ODYYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	For the Three Months Ended April 30,		For the Nine Months Ended April 30,
	2025	2024	2025	2024
Research and development expense	$–	$–	$–	$65,766
Stock-based compensation	11,781	51,483	108,399	1,051,671
General and administrative expense	117,274	320,888	756,676	1,259,606
Loss from operations	(129,055)	(372,371)	(865,075)	(2,377,043)
Gain on sale of asset	–	–	–	16,400,687
Change in fair value of investment in common stock	(61,357)	(367,929)	(432,053)	(1,700,909)
Interest expense	(61,395)	(102,227)	(193,611)	(434,689)
Other income (expense), net	64	186	(36)	9,144
Net income (loss)	(251,743)	(842,341)	(1,490,775)	11,897,190
Deemed dividend - warrants	–	–	–	(63,455)
Net income (loss) attributable to common stockholders	$(251,743)	$(842,341)	$(1,490,775)	$11,833,735
Basic net income (loss) per share attributable to common stockholders	$(0.00)	$(0.01)	$(0.01)	$0.13
Diluted net income (loss) per share attributable to common stockholders	$(0.00)	$(0.01)	$(0.01)	$0.11
Shares used for basic net income (loss) per share attributable to common stockholders	104,709,763	103,789,222	104,709,763	94,496,866
Shares used for diluted net income (loss) per share attributable to common stockholders	104,709,763	103,789,222	104,709,763	113,895,608

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.